Ariclaim var kun mere effektivt end placebo hos patienter, som havde over 14 inkontinensepisoder om ugen (moderat til svær SUI) ved undersøgelsens start.
Ariclaim was more effective than placebo only in patients who had more than 14 incontinence episodes per week (moderate to severe SUI) at the start of the study.